Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5

Onishi, Rika; Ikemoto, Sena; Shiota, Aoi et al.

International Journal of Pharmaceutics, 2024, 662, 124480

Number of Access:886（2025-09-01 16:20 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/98172

Link to primary information 

File Format Terms of use Size Views Date.Available Description information
IntJPharm_662_124480 pdf None 2.30 MB 71 2024.09.27  
Creative Commons : Attribution - NonCommercial - NoDerivatives

Item Information

Output File Export EndNote Basic Export Mendeley

Title
Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5
Creator
CreatorName
Onishi, Rika
CreatorName
Ikemoto, Sena
CreatorName
Shiota, Aoi
NRID
1000020977342 1000020977342
researchmap permalink
tsukamoto-t tsukamoto-t
CreatorName
Tsukamoto, Tomohito
CreatorName
Asayama, Akira
NRID
1000080513449 1000080513449
CreatorName
Tachibana, Masashi
NRID
1000070370939 1000070370939
researchmap permalink
read0165081 read0165081
Scopus Author ID
7003748169 7003748169
CreatorName
Sakurai, Fuminori
NRID
1000050311387 1000050311387
researchmap permalink
read0165079 read0165079
Scopus Author ID
57195381326 57195381326
CreatorName
Mizuguchi, Hiroyuki
Subject
Adenovirus vector
Arg-Gly-Asn (RGD) peptide
Fiber-mutant
Vaccine
αv-integrin
Description
Onishi R., Ikemoto S., Shiota A., et al. Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5. International Journal of Pharmaceutics 662, 124480 (2024); https://doi.org/10.1016/j.ijpharm.2024.124480.
Abstract
Adenovirus (Ad) vectors based on human adenovirus serotype 5 (Ad5) have attracted significant attention as vaccine vectors for infectious diseases. However, the effectiveness of Ad5 vectors as vaccines is often inhibited by the anti-Ad5 neutralizing antibodies retained by many adults. To overcome this drawback, we focused on human adenovirus serotype 35 (Ad35) vectors with low seroprevalence in adults. Although Ad35 vectors can circumvent anti-Ad5 neutralizing antibodies, vector yields of Ad35 vectors are often inferior to those of Ad5 vectors. In this study, we developed novel Ad35 vectors containing the Ad5 E4 orf 4, 6, and 6/7 or the Ad5 E4 orf 6 and 6/7 for efficient vector production, and compared their properties. These E4-modified Ad35 vectors efficiently propagated to a similar extent at virus titers comparable to those of Ad5 vectors. An Ad35 vector containing the Ad5 E4 orf 4, 6, and 6/7 mediated more efficient transduction than that containing the Ad5 E4 orf 6 and 6/7 in human cultured cells. Furthermore, insertion of an arginine-glycine-aspartate (RGD) peptide in the fiber region of an Ad35 vector containing the Ad5 E4 orf 4, 6, and 6/7 significantly improved the transgene product-specific antibody production following intramuscular administration in mice. The Ad35 vector containing the RGD peptide mediated efficient vaccine effects even in the mice pre-immunized with an Ad5.
Publisher
Elsevier B.V.
Source Title
International Journal of Pharmaceutics
Volume (Issue)
662
Page
124480
Date of Issued
2024-09-05
Language
English
Handle URL
https://hdl.handle.net/11094/98172
PISSN
03785173
eISSN
18733476
Relation.isIdenticalTo
DOI (Publisher Version)
https://doi.org/10.1016/j.ijpharm.2024.124480
Access Rights
open access
CopyRight
This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
oaire:version
Version of Record
Category
学術雑誌論文 Journal Article